Variant Assessment for Reduced Penetrance Diseases

Heritable disorders can often be linked back to a specific gene or genetic variant which transmits the risk of disease across generations. In most cases, the penetrance, or risk of being affected by the disease, for a pathogenic variant carrier is less than 100%. For an increasing number of disorders, the penetrance is even lower (20-50%), which begins to confound our ability to understand the relationship between disease risk and a specific genetic variant. At this level, classical tools, including family and functional studies, for assessment of variant pathogenicity loose power. This webinar will address the utility of the different lines of evidence in the classification of variants in moderate penetrance disease and recommended modifications to multivariate analysis in this setting. 
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Innovative OTC Remedies for Seasonal Flu Epidemic

questexweb

It was reported that over 79,000 people died of flu in the U.S. in the winter of 2017-2018, which was the highest death toll in four decades.1 It seems like the 2018-2019 flu season isn’t so bad. How are sales of OTC drugs impacted by the severity of flu seasons? Are there any opportunities for new products to capture market share? How can companies ensure reliable supply of OTC medications based upon expected spikes in demand?
Watch Now

cDPI: Line extension with capsule-based inhalation drug delivery

Drug delivery via the inhalation route is currently in demand for treatment of various diseases including asthma and chronic obstructive pulmonary disorders.
Watch Now

An Equivalent Alternative to LAL Assays The Recombinant Factor C Assay

Worldwide, there is a growing appeal in the pharmaceutical industry for recombinant technologies that help alleviate, and eventually replace, the use of animal resources for endotoxin testing purposes.
Watch Now

Excipients and Formulation Assessments of Complex Generic Products

The goal of this webinar is to provide an overview of the regulatory framework, scientific concepts, product-specific challenges, and best practices related to development of complex generic drug products.
Watch Now

Spotlight

resources